Anita Brogan

PhD

VP, VALUE EVIDENCE, MODELING & COMMUNICATION

San Diego, CA

"People will forget what you said, people will forget what you did, but people will never forget how you made them feel.”– Maya Angelou

Areas of Expertise

  • Cost-effectiveness and budget-impact modeling
  • Infectious disease modeling
  • Economic assessment of healthcare interventions for AMCP, HTA, and NITAGs
  • User-friendly tools in Excel and other platforms

Biography

Anita Brogan is an established Health Economics leader with over 20 years of experience designing and building economic analyses to support value assessment and patient access for new healthcare interventions. She collaborates with clients to develop user-friendly global and country-specific models designed to both strategically demonstrate value and employ robust scientific methods. Technically skilled in simple and complex modeling methodologies, Anita works with clients to identify the most appropriate methods for each situation. Anita’s modeling expertise includes cost-effectiveness, budget-impact, optimization, population, and other analyses, with a specialty in HIV and infectious disease modeling. Her modeling work has successfully supported market access, HTA submissions, and usage recommendations for new interventions in a variety of therapeutic areas and markets.

Prior to joining AESARA, Anita led health economic modeling work at RTI Health Solutions for 22 years. She holds a PhD in Operations Research from the University of North Carolina at Chapel Hill and serves on the Pharmacoeconomics journal editorial board. Anita loves teaching and has presented workshops and short courses on decision-analytic modeling techniques in a variety of venues, including ISPOR and AMCP conferences. She currently serves on the ISPOR program committee and education council. Anita is co-author of the book “Budget-Impact Analysis of Health Care Interventions: A Practical Guide.”

Key accomplishments

  • Designed, developed, and published an innovative cost-effectiveness analysis demonstrating that long-acting pre-exposure prophylaxis could substantially reduce new cases of HIV-1 and yield cost savings for subgroups disproportionately affected by HIV. The article supported reimbursement and won the 2024 Tufts-CEVR Cost-effectiveness Paper of the Year

  • Developed economic analyses for new interventions in a variety of therapeutic areas and markets that supported patient access and favorable HTA recommendations

  • Book co-author on the seminal guide for budget-impact analysis and instructor for core ISPOR budget-impact analysis short course

Key publications

  • Mauskopf J, Earnshaw SR, Brogan, AJ, Wolowacz S, Brodtkorb TH. Budget-Impact Analysis of Health Care Interventions: A Practical Guide. Springer International Publishing AG, 2017.
  • Brogan AJ, Davis AE, Mellott CE, Fraysse J, Metzner AA, Oglesby AK. Cost-effectiveness of cabotegravir long-acting for HIV pre-exposure prophylaxis in the United States. Pharmacoeconomics. 2024 Apr;42(4):447-61.
  • Brogan AJ, Zhang K. From data to dialogue: mastering conversations to amplify HEOR impact and influence. Fast Facts session, ISPOR 2025; May 15, 2025. Montreal, Canada.
  • Bisanzio D, Davis AE, Talbird SE, Van Effelterre T, Metz L, Gaudig M, Mathieu VO, Brogan AJ. Targeted preventive vaccination campaigns to reduce Ebola outbreaks: an individual-based modeling study. Vaccine. 2022 Dec 14;S0264-410X(22):01449-9.
  • Brogan AJ, Talbird SE, Davis AE, La EM, Kumar PN. The cost-effectiveness and budget impact of ibalizumab-uiyk for adults with multidrug-resistant HIV-1 infection in the United States. Pharmacoeconomics. 2021 Apr;39(4):421-32.
  • Brogan AJ, Talbird SE, Davis AE, Wild L, Flanagan D. Is increased screening and early antiretroviral treatment for HIV-1 worth the investment? An analysis of the public health and economic impact of improvement in the UK. HIV Med. 2019 Nov;20(10):668-80.
  • Wasserman M, Lucas A, Jones D, Wilson M, Hilton B, Vyse A, Madhava H, Brogan AJ. Dynamic transmission modelling to address infant pneumococcal conjugate vaccine schedule modifications in the UK. Epidemiol Infect. 2018 Oct;146(14):1797-806.
  • Brogan AJ, Talbird SE, Davis AE, Thommes EW, Meier G. Cost-effectiveness of seasonal quadrivalent versus trivalent influenza vaccination in the United States: a dynamic transmission modeling approach. Hum Vaccin Immunother. 2017 Mar 4;13(3):533-42. 
  •  

Education

  • PhD, Operations Research, University of North Carolina at Chapel Hill, 2003
  • MS, Operations Research, University of North Carolina at Chapel Hill, 1999
  • BS, Mathematics, Harvey Mudd College, 1997

My letter

π — In Mathematics, the transcendental constant π appears in formulas related to circles and spheres. The uppercase Π symbol is used to denote the product of a sequence. For me, circles and multiplication represent individuals coming together, honoring the perspective each person brings, and accomplishing more in partnership than we could alone. I believe our most effective work comes from collaborating in teams that intentionally build trust and mutual understanding. Listening and asking questions to identify ideas, concerns, and feedback help us move forward together, jointly benefit from all contributions, and develop influential work that makes a difference in people’s lives.

Contact us

Fill out the form below, and we will be in touch shortly.